Blastic plasmacytoid dendritic cell neoplasm

From HemOnc.org - A Hematology Oncology Wiki
(Redirected from BPDCN)
Jump to: navigation, search
Section editor
MartinSchoen.jpg
Martin W. Schoen, MD, MPH
Saint Louis University
St. Louis, MO

Social-twitter-icon.pngmwschoen
1 regimens on this page
1 variants on this page


All lines of therapy

Tagraxofusp monotherapy

back to top

Regimen

Study Years of enrollment Evidence
Frankel et al. 2014 (STU 012013-061) NR Phase I/II, <20 pts
Pemmaraju et al. 2019 (STML-401-0114) 2014-2017 Phase I/II (RT)

Chemotherapy

21-day cycles

References

  1. STU 012013-061: Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. link to original article link to PMC article PubMed
  2. STML-401-0114: Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. link to original article contains verified protocol PubMed